ELC Group appoints former TOPRA president

Dr Paolo Biffignandi joins ELC Group’s Advisory Board

Dr Paolo Biffignandi, former president of The Organisation for Professionals in Regulatory Affairs (TOPRA), has joined the ELC Group’s Advisory Board. ELC is a pan-European pharmaceutical regulatory affairs organisation.

Dr Biffignandi, a renowned physician, with PhDs in endocrinology and pharmacology, is a Fellow of TOPRA, as well as an Overseas Fellow of the Royal Society of Medicine (UK). He brings more than 30 years' experience in Regulatory Affairs and pharmacovigilance to ELC Group’s Advisory Board.

Commenting on his appointment, Dr Biffignandi said: 'ELC Group is the industry expert, and I'm pleased to accept this opportunity to join its Advisory Board and to contribute to its continued strategic success.'

You may also like

Regulatory

ELC Group signs €1.5m regulatory affairs contract with Chinese pharma company

Endorses its Concept to Commercialisation approach to regulatory affairs consultancy services
Regulatory

ELC Group expands corporate presence in Czech Republic

Major contract wins in China and US fuel latest move into larger premises in Prague
Regulatory

ELC Group expands its offices in Ahmedabad, India

Regulatory affairs specialist continues its growth in the country
Regulatory

ELC Group opens new office in Mumbai, India

To be headed by Pooja Raj, general manager, regulatory affairs
Regulatory

ELC Group establishes global hq in Cambridge, UK

Follows year of exceptional revenue growth for regulatory affairs organisation
Regulatory

Pfizer and BioNTech’s COMIRNATY COVID-19 vaccine wins FDA approval for seniors and high-risk individuals

The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies
Regulatory

Roca secures EMA recognition of radiation maculopathy as a distinct indication and Orphan Drug Designation

Roca Therapeutics (Roca) announces the granting of Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for its lead clinical candidate, RCT002, to treat radiation maculopathy
Subscribe now